



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

## \*CORRESPONDENCE

Markus Uhrberg  
✉ Markus.Uhrberg@med.uni-  
duesseldorf.de

RECEIVED 11 September 2023

ACCEPTED 12 September 2023

PUBLISHED 22 September 2023

## CITATION

Bennstein SB, Weinhold S, Degistirici Ö,  
Oostendorp RAJ, Raba K, Kögler G,  
Meisel R, Walter L and Uhrberg M (2023)  
Corrigendum: Efficient *in vitro* generation  
of IL-22-secreting ILC3 from CD34+  
hematopoietic progenitors in a human  
mesenchymal stem cell niche.  
*Front. Immunol.* 14:1292209.  
doi: 10.3389/fimmu.2023.1292209

## COPYRIGHT

© 2023 Bennstein, Weinhold, Degistirici,  
Oostendorp, Raba, Kögler, Meisel, Walter and  
Uhrberg. This is an open-access article  
distributed under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#). The  
use, distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in  
this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Corrigendum: Efficient *in vitro* generation of IL-22-secreting ILC3 from CD34+ hematopoietic progenitors in a human mesenchymal stem cell niche

Sabrina B. Bennstein<sup>1</sup>, Sandra Weinhold<sup>1</sup>, Özer Degistirici<sup>2</sup>,  
Robert A. J. Oostendorp<sup>3</sup>, Katharina Raba<sup>1</sup>, Gesine Kögler<sup>1</sup>,  
Roland Meisel<sup>2</sup>, Lutz Walter<sup>4</sup> and Markus Uhrberg<sup>1\*</sup>

<sup>1</sup>Institute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, <sup>2</sup>Division of Pediatric Stem Cell Therapy, Clinic for Pediatric Oncology, Hematology and Clinical Immunology, Center for Children and Adolescence Health, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany, <sup>3</sup>Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Internal Medicine III – Hematology and Oncology, Laboratory of Stem Cell Physiology, Munich, Germany, <sup>4</sup>Primate Genetics Laboratory, German Primate Center, Leibniz Institute for Primate Research, Göttingen, Germany

## KEYWORDS

CD34 cells<sup>+</sup>, mesenchymal stem cells, umbilical cord stem cells (UCSC), innate lymphoid cells (ILCs), ILC3, hematopoietic stem and progenitor cells, GMP—Good Manufacturing Practice

## A Corrigendum on

**Efficient *in vitro* generation of IL-22-secreting ILC3 from CD34+ hematopoietic progenitors in a human mesenchymal stem cell niche**

by Bennstein SB, Weinhold S, Degistirici Ö, Oostendorp RAJ, Raba K, Kögler G, Meisel R, Walter L and Uhrberg M (2021) *Front. Immunol.* 12:797432. doi: 10.3389/fimmu.2021.797432

In the published article, there was an error in the Funding statement. A funding source of the author Roland Meisel was mistakenly not included in the publication. The correct Funding statement appears below.

## Funding

This work was supported by funds from the Düsseldorf School of Oncology (funded by the Comprehensive Cancer Center Düsseldorf/Deutsche Krebshilfe and the Medical Faculty HHU Düsseldorf) and the Deutsche Forschungsgemeinschaft (DFG) FOR2033, TP B3 (RO), SPP1937-UH91/8-1 and UH91/10-1 (both MU). This work was partially supported by funds from the Bundesministerium für Bildung und Forschung (BMBF) MyPred, 01GM1911E to RM.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated